MCID: CNT060
MIFTS: 44

Central Serous Chorioretinopathy

Categories: Bone diseases, Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Central Serous Chorioretinopathy

MalaCards integrated aliases for Central Serous Chorioretinopathy:

Name: Central Serous Chorioretinopathy 54 60 74
Central Serous Chorioretinopathy After Bone Marrow Transplantation 54
Central Serous Choroidopathy 54
Cscr 60

Characteristics:

Orphanet epidemiological data:

60
central serous chorioretinopathy
Inheritance: Not applicable;

Classifications:

Orphanet: 60  
Rare eye diseases


External Ids:

ICD10 via Orphanet 35 H35.7
UMLS via Orphanet 75 C0730328
Orphanet 60 ORPHA443079
UMLS 74 C0730328

Summaries for Central Serous Chorioretinopathy

NIH Rare Diseases : 54 Central serous chorioretinopathy is a disease that causes fluid to build up under the retina, the back part of the inner eye that sends sight information to the brain. The fluid leaks from the choroid (the blood vessel layer under the retina). The cause of this condition is unknown but stress can be a risk factor. Signs and symptoms include dim and blurred blind spot in the center of vision, distortion of straight lines and seeing objects as smaller or farther away. Many cases of central serous chorioretinopathy improve without treatment after 1-2 months. Laser treatment may be an option for other individuals.

MalaCards based summary : Central Serous Chorioretinopathy, also known as central serous chorioretinopathy after bone marrow transplantation, is related to choroiditis and kuhnt-junius degeneration. An important gene associated with Central Serous Chorioretinopathy is SERPINE1 (Serpin Family E Member 1), and among its related pathways/superpathways are Complement and coagulation cascades and Cell adhesion_ECM remodeling. The drugs Verteporfin and Eplerenone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone, and related phenotype is renal/urinary system.

Related Diseases for Central Serous Chorioretinopathy

Diseases related to Central Serous Chorioretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 choroiditis 30.7 ARMS2 CFH
2 kuhnt-junius degeneration 30.6 ARMS2 CFH
3 bestrophinopathy 11.7
4 retinal detachment 10.8
5 macular degeneration, age-related, 1 10.6
6 neutrophil migration 10.6
7 degos 'en cocarde' erythrokeratoderma 10.5
8 sleep apnea 10.4
9 coronary heart disease 1 10.3
10 heart disease 10.3
11 vogt-koyanagi-harada disease 10.3
12 macular retinal edema 10.3
13 multiple sclerosis 10.3
14 macular dystrophy, dominant cystoid 10.3
15 salla disease 10.3
16 ulcerative colitis 10.3
17 colitis 10.3
18 uveitis 10.3
19 impotence 10.3
20 optic nerve disease 10.3
21 melanoma 10.3
22 retinal vascular disease 10.3
23 neuropathy 10.3
24 catastrophic antiphospholipid syndrome 10.3 CFH SERPINE1
25 fibrinolytic defect 10.3 PLAT SERPINE1
26 plasminogen activator inhibitor-1 deficiency 10.2 PLAT SERPINE1
27 argentine hemorrhagic fever 10.2 PLAT SERPINE1
28 carotid artery thrombosis 10.2 PLAT SERPINE1
29 acute cor pulmonale 10.2 PLAT SERPINE1
30 thrombophlebitis 10.2 PLAT SERPINE1
31 acute pulmonary heart disease 10.2 PLAT SERPINE1
32 coronary thrombosis 10.2 PLAT SERPINE1
33 chronic venous insufficiency 10.2 PLAT SERPINE1
34 venous insufficiency 10.2 PLAT SERPINE1
35 hepatic veno-occlusive disease 10.2 PLAT SERPINE1
36 vein disease 10.2 PLAT SERPINE1
37 systemic lupus erythematosus 10.2
38 pituitary adenoma 4, acth-secreting 10.2
39 retinitis pigmentosa 10.2
40 leber congenital amaurosis 4 10.2
41 anxiety 10.2
42 hemangioma 10.2
43 keratoconus 10.2
44 myopia 10.2
45 conn's syndrome 10.2
46 telangiectasis 10.2
47 neuritis 10.2
48 retinitis 10.2
49 acth-secreting pituitary adenoma 10.2
50 macular holes 10.2

Graphical network of the top 20 diseases related to Central Serous Chorioretinopathy:



Diseases related to Central Serous Chorioretinopathy

Symptoms & Phenotypes for Central Serous Chorioretinopathy

MGI Mouse Phenotypes related to Central Serous Chorioretinopathy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.92 C4B CFH NR3C2 SERPINE1

Drugs & Therapeutics for Central Serous Chorioretinopathy

Drugs for Central Serous Chorioretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verteporfin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 129497-78-5
2
Eplerenone Approved Phase 4,Phase 2,Phase 3,Not Applicable 107724-20-9 443872 150310
3
Ranibizumab Approved Phase 4,Phase 1,Phase 2 347396-82-1 459903
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Natriuretic Agents Phase 4,Phase 2,Phase 3,Not Applicable
6 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 diuretics Phase 4,Phase 2,Phase 3,Not Applicable
8 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
9 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 3,Not Applicable
10 Mineralocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
11 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
13 Dermatologic Agents Phase 4,Phase 2,Phase 1,Not Applicable
14 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Photosensitizing Agents Phase 4,Phase 1,Phase 2,Not Applicable
17 Pharmaceutical Solutions Phase 4
18
Bevacizumab Approved, Investigational Phase 2, Phase 3,Not Applicable 216974-75-3
19
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760 44516822
20
Trametinib Approved Phase 3,Phase 2 871700-17-3 11707110
21 Antineoplastic Agents, Immunological Phase 2, Phase 3,Not Applicable
22 Protein Kinase Inhibitors Phase 3,Phase 2
23
leucovorin Approved Phase 2 58-05-9 143 6006
24
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
25
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
26
Zinc Approved, Investigational Phase 2 7440-66-6 32051
27
Copper Approved, Investigational Phase 2 7440-50-8 27099
28
Tocopherol Approved, Investigational Phase 2 1406-66-2 14986
29
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
30
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
31
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
32
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
33
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
34
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
35
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
36
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576
37
Finasteride Approved Phase 1, Phase 2,Phase 2 98319-26-7 57363
38
Gemcitabine Approved Phase 2 95058-81-4 60750
39
Brinzolamide Approved Phase 2 138890-62-7 68844
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
41
Manganese Approved, Nutraceutical Phase 2 7439-96-5 27854
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
43
Lutein Approved, Investigational, Nutraceutical Phase 2 127-40-2 6433159
44
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 54670067 5785
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
46
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
47
Lactitol Investigational Phase 1, Phase 2,Not Applicable 585-88-6, 585-86-4 493591
48 Tocotrienol Investigational Phase 2 6829-55-6
49 Anecortave Investigational Phase 1, Phase 2 10184-70-0
50 Folate Phase 2

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Completed NCT01797861 Phase 4
2 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4 Inspra (eplerenone)
3 Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Completed NCT01574430 Phase 4
4 Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Recruiting NCT03079141 Phase 4 Eplerenone
5 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
6 PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
7 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
8 Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Unknown status NCT00418431 Phase 2, Phase 3 Intravitreal injection of Bevacizumab
9 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Completed NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
10 Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy Recruiting NCT02735213 Phase 2, Phase 3
11 Methotrexate for Central Serous Chorioretinopathy Treatment Trial Unknown status NCT01633983 Phase 2 Methotrexate;Delayed treatment
12 Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT02153125 Phase 2 Eplerenone
13 Eplerenone for Central Serous Chorioretinopathy Completed NCT01822561 Phase 2 Eplerenone 50mg
14 Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Completed NCT02354170 Phase 2 Mifepristone;Placebo
15 High-dose Antioxidants for Central Serous Chorioretinopathy Completed NCT00963131 Phase 2 antioxidants tablets
16 Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Completed NCT00489840 Phase 1, Phase 2 Anecortave Acetate Sterile suspension 15 mg;Anecortave Acetate
17 Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Completed NCT00817245 Phase 1, Phase 2 omeprazole, Amoxicillin, metronidazole
18 The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Completed NCT01710332 Phase 2 Intravitreal Aflibercept Injection
19 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
20 Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01325181 Phase 1, Phase 2 Verteporfin;ranibizumab
21 A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Completed NCT00211393 Phase 2 ketoconazole
22 Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Completed NCT00987077 Phase 2
23 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
24 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT00837252 Phase 1, Phase 2 Finasteride
25 Topical Interferon Gamma-1b for Central Serous Chorioretinopathy Completed NCT01468337 Phase 1, Phase 2 Interferon gamma-1b
26 Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Completed NCT00211445 Phase 2 verteporfin
27 Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer Completed NCT01231581 Phase 2 GSK1120212;Gemcitabine;Placebo
28 Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Recruiting NCT01975103 Phase 2
29 Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy Not yet recruiting NCT03542006 Phase 2 Brinzolamide Ophthalmic
30 Finasteride for Chronic Central Serous Chorioretinopathy Terminated NCT01585441 Phase 2 Finasteride;Placebo
31 Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Completed NCT00403325 Phase 1 rhuFab V2 [ranibizumab] ( Lucentis )
32 Eye Patch Therapy for Central Serous Retinopathy (CSR) Completed NCT02036632 Phase 1
33 The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Unknown status NCT01630863 Not Applicable
34 The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Unknown status NCT00864773 Not Applicable
35 Pseudo-PDT in Central Serous Chorioretinopathy Unknown status NCT02799992 Not Applicable
36 Multimodal Imaging in Central Serous Chorioretinopathy Unknown status NCT02889185 Not Applicable
37 Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers Unknown status NCT02815176
38 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884 Not Applicable
39 Investigation of Vascular Pathology in Eye Diseases Using Using Optical Coherence Tomography Angiography (OCT-A) Unknown status NCT02811536
40 Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Completed NCT03950089
41 Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Completed NCT01019668 Not Applicable Verteporfin PDT, half-dose;verteporfin PDT, half-fluence
42 Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy Completed NCT03758963 Not Applicable
43 Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Completed NCT01327170 Not Applicable
44 Treatment Trial for Acute Central Serous Chorioretinopathy Completed NCT02784665 Not Applicable
45 Central Serous Chorioretinopathy: Etiology, Course and Prognosis Completed NCT01378130
46 Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Completed NCT00803517
47 Eplerenone for the Treatment of Central Serous Chorioretinopathy Completed NCT01990677 Not Applicable 25mg Eplerenone;Placebo
48 Persona of Central Serous Chorioretinopathy Completed NCT02819622
49 Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Completed NCT03339856 Not Applicable
50 Effects of OCTA-guided PDT in Acute CSC Completed NCT03497000 Not Applicable

Search NIH Clinical Center for Central Serous Chorioretinopathy

Genetic Tests for Central Serous Chorioretinopathy

Anatomical Context for Central Serous Chorioretinopathy

MalaCards organs/tissues related to Central Serous Chorioretinopathy:

42
Eye, Retina, Bone, Bone Marrow, Brain, Heart, Endothelial

Publications for Central Serous Chorioretinopathy

Articles related to Central Serous Chorioretinopathy:

(show top 50) (show all 1199)
# Title Authors Year
1
Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. ( 31014765 )
2019
2
Dome shaped maculopathy with tilted disc misdiagnosed as central serous chorioretinopathy. ( 31036744 )
2019
3
Exome sequencing in patients with chronic central serous chorioretinopathy. ( 31036833 )
2019
4
Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). ( 31037488 )
2019
5
Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy. ( 31037490 )
2019
6
Intranasal Corticosteroids and Central Serous Chorioretinopathy: A Report and Review of the Literature. ( 31049263 )
2019
7
Double Gutter in Central Serous Chorioretinopathy. ( 31070684 )
2019
8
Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. ( 31079056 )
2019
9
Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. ( 30110697 )
2019
10
Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. ( 30194380 )
2019
11
Masqueraders of central serous chorioretinopathy. ( 30243734 )
2019
12
Detection of secondary choroidal neovascularization in chronic central serous chorioretinopathy by swept source-optical coherence tomography angiography. ( 30284407 )
2019
13
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. ( 30308202 )
2019
14
Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. ( 30378259 )
2019
15
Choriocapillaris flow features and choroidal vasculature in the fellow eyes of patients with acute central serous chorioretinopathy. ( 30397792 )
2019
16
Statement of the Professional Association of German Ophthalmologists (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018. ( 30411167 )
2019
17
Re: van Dijk et al: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE trial (Ophthalmology. 2018;125:1547-1555). ( 30470544 )
2019
18
Central serous chorioretinopathy in elderly subjects: angiographic and tomographic characteristics. ( 30564905 )
2019
19
An unusual case of multifocal central serous chorioretinopathy with low serum cortisol managed using eplerenone. ( 30574936 )
2019
20
Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy. ( 30602447 )
2019
21
Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years. ( 30610228 )
2019
22
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. ( 30616898 )
2019
23
Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. ( 30617579 )
2019
24
OCT Angiography of the Choriocapillaris in Central Serous Chorioretinopathy: A Quantitative Subgroup Analysis. ( 30617944 )
2019
25
Investigating the Hypothesis of Stress System Dysregulation as A Risk Factor for Central Serous Chorioretinopathy: A Literature Mini-Review. ( 30624085 )
2019
26
ELONGATED PHOTORECEPTOR OUTER SEGMENT LENGTH AND PROGNOSIS OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. ( 30640283 )
2019
27
Optical Coherence Tomography Angiography Findings in Chronic Central Serous Chorioretinopathy After Photodynamic Therapy. ( 30640392 )
2019
28
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy. ( 30659849 )
2019
29
Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India. ( 30672479 )
2019
30
Quetiapine associated Central Serous Chorioretinopathy: Implicit role of serotonin and dopamine pathways. ( 30672500 )
2019
31
Pharmacotherapy of central serous chorioretinopathy: review of the current treatments. ( 30674250 )
2019
32
Predictive Factors of Response to Mineralocorticoid Receptor Antagonist in Nonresolving Central Serous Chorioretinopathy. ( 30683307 )
2019
33
A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. ( 30710172 )
2019
34
Exome sequencing in families with chronic central serous chorioretinopathy. ( 30724488 )
2019
35
Effect of Serous Retinal Detachment on the Measurement of Axial Length in Central Serous Chorioretinopathy. ( 30746913 )
2019
36
Optical coherence tomography angiography findings in fellow eyes of choroidal neovascularisation associated with central serous chorioretinopathy. ( 30798261 )
2019
37
Central serous chorioretinopathy with and without steroids: A multicenter survey. ( 30818363 )
2019
38
Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. ( 30824822 )
2019
39
Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy ( 30829023 )
2019
40
Central Serous Chorioretinopathy: A Complication Associated with Behçet’s Disease Treatment ( 30829024 )
2019
41
Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report. ( 30849939 )
2019
42
Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. ( 30850639 )
2019
43
Clinical characteristics of pachydrusen in central serous chorioretinopathy. ( 30852634 )
2019
44
Optical Coherence Tomography Angiography Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy. ( 30871715 )
2019
45
Increased risk of central serous chorioretinopathy following end-stage renal disease: A nationwide population-based study. ( 30882685 )
2019
46
COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. ( 30897068 )
2019
47
A Backward Glance at Chronic Central Serous Chorioretinopathy. ( 30910041 )
2019
48
Re: van Dijk et al.: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial (Ophthalmology. 2018;125:1547-1555). ( 30910047 )
2019
49
The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy. ( 30922273 )
2019
50
Optical Coherence Tomography Angiography Quantitative Assessment of Choriocapillaris Blood Flow in Central Serous Chorioretinopathy. ( 30935474 )
2019

Variations for Central Serous Chorioretinopathy

Expression for Central Serous Chorioretinopathy

Search GEO for disease gene expression data for Central Serous Chorioretinopathy.

Pathways for Central Serous Chorioretinopathy

Pathways related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.07 C4B CFH PLAT SERPINE1
2 11.04 PLAT SERPINE1
3 10.99 C4B CFH
4 10.07 PLAT SERPINE1

GO Terms for Central Serous Chorioretinopathy

Cellular components related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.02 C4B CFH PLAT SERPINE1 SLC7A5

Biological processes related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 complement activation GO:0006956 8.96 C4B CFH
2 fibrinolysis GO:0042730 8.62 PLAT SERPINE1

Sources for Central Serous Chorioretinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....